Synthesis of Ursolic Acid-based Hybrids: In Vitro Antibacterial, Cytotoxicity Studies, In Silico Physicochemical and Pharmacokinetic Properties.

BACKGROUND: There is a critical need for the discovery of novel and effective antibacterial or anticancer molecules. OBJECTIVES: Amine-linked ursolic acid-based hybrid compounds were prepared in good yields in the range of 60-68%. METHODS: Their molecular structures were successfully confirmed using different spectroscopic methods including 1H/13C NMR, UHPLC-HRMS and FTIR spectroscopy. The in vitro cytotoxicity of some of these hybrid molecules against three human tumour cells, such as MDA-MB23, MCF7, and HeLa was evaluated using the MTT colorimetric method. RESULT: Their antibacterial efficacy was evaluated against eleven bacterial pathogens using a serial dilution assay. Majority of the bacterial strains were inhibited significantly by compounds 17 and 24, with the lowest MIC values in the range of 15.3-31.25 µg/mL. Compound 16 exhibited higher cytotoxicity against HeLa cells than ursolic acid, with an IC50 value of 43.64 g/mL. CONCLUSION: The in vitro antibacterial activity and cytotoxicity of these hybrid compounds demonstrated that ursolic acid-based hybrid molecules are promising compounds. Further research into ursolic acid-based hybrid compounds is required.

Synthesis of Ester-Linked Ursolic Acid-Based Hybrid Compounds: Potential Antibacterial and Anticancer Agents.

The molecular hybridization of two or more drugs into a single molecule is an effective drug design approach to reduce pill burden and improve patient treatment adherence. Ursolic acid-based hybrid compounds were synthesized and characterized followed by molecular docking studies. In vitro studies against various bacterial strains and human cancer cells (MDA-MB-231, HeLa, and MCF-7) were performed. Compounds 14-19, 21, 34, 31, and 30 demonstrated significant antibacterial activities with MIC values of 15.625 µg/ml. Compounds 29 and 34 were more cytotoxic than ursolic acid, with IC50 values of 46.99 and 48.18 µg/ml. Compounds 29 and 34 in the docking studies presented favourable binding interactions and better docking energy against the Epidermal Growth Factor Receptor (EGFR) than the parent compound, ursolic acid. The findings revealed that the ursolic acid scaffold is a promising precursor for the development of molecules with promising anticancer and antimicrobial activities. However, more studies are needed to fully understand their mode of action.

New isoflavan from Erythrina livingstoniana.

Chemical investigation of the root wood of Erythrina livingstoniana led to the isolation of one previously undescribed isoflavan (3S,3″R)-7-hydroxy-2'-methoxy-[3″-hydroxy-2″,2″-dimethylpyrano (3',4')] isoflavan 1, together with eleven known compounds 2-12. The structure of compound 1 was elucidated on the basis of extensive spectroscopic and spectrometric analyses (1 D and 2 D-NMR and APCI-HRMS), with absolute configurations established by comparison of experimental and DFT calculated ECD data. The assignment of the absolute configurations of C-3 and C-3″ of compounds 2 and 3, respectively, were reported for the first time. Compounds 1 - 4 were evaluated for their antibacterial activities in vitro against E. coli ATCC 25922 and S. aureus ATCC 25923. Compound 1 exhibited moderate antibacterial activity with MIC value of 0.063 mg/mL against the clinically relevant risk-group 2 (RG-2) bacterium S. aureus.

Characterization of an Exopolymeric Flocculant Produced by a Brachybacterium sp.

We evaluated the bioflocculant production potential of an Actinobacteria, which was isolated from a freshwater environment in the Eastern Cape province of South Africa. 16S rDNA nucleotide sequencing analyses revealed that the actinobacteria belongs to the Brachybacterium genus, and the sequences were deposited in the GenBank as Brachybacterium sp. UFH, with accession number HQ537131. Optimum fermentation conditions for bioflocculant production by the bacteria include an initial medium pH of 7.2, incubation temperature of 30 °C, agitation speed of 160 rpm and an inoculum size of 2% (vol/vol) of cell density 3.0 × 108 CFU/mL. The carbon, nitrogen and cation sources for optimum bioflocculant production were maltose (83% flocculating activity), urea (91.17% flocculating activity) and MgCl2 (91.16% flocculating activity). Optimum bioflocculant production coincided with the logarithmic growth phase of the bacteria, and chemical analyses of the bioflocculant showed 39.4% carbohydrate and 43.7% protein (wt/wt). The mass ratio of neutral sugar, amino sugar and uronic acids was 1.3:0.7:2.2. Fourier transform infrared spectroscopy (FTIR) indicated the presence of carboxyl, hydroxyl and amino groups, amongst others, typical for heteropolysaccharide and glycosaminoglycan polysaccharides. Bioflocculant pyrolysis showed thermal stability at over 600 °C, while scanning electron microscope (SEM) imaging revealed a maze-like structure of interlaced flakes. Its high flocculation activity suggests its suitability for industrial applicability.